Gilead Sciences (GILD): Future Prospects and Stock Price Outlook

This site is a great place for me (@mifsee(2) has been working on company and stock analysis while learning privately.

This is only a record of my personal analysis and the contents may contain errors or information that differs from the actual situation. Please understand in advance when viewing this site.

Introduction.

Prolonged inflation and recession fears have made the U.S. market outlook increasingly uncertain.

In order to respond to these changes in market conditions, the portfolio must be adjusted. In particular, it is effective to incorporate defensive stocks with stable earnings. We focused on Gilead Sciences (GILD) as a candidate for this purpose.

Gilead Sciences is a biopharmaceutical company that develops and markets drugs to treat life-threatening diseases such as HIV, viral hepatitis, and cancer. The company has strong fundamentals and is particularly attractive due to its ample cash flow and high dividend payout.

This article details Gilead Sciences' (GILD) business, competitive advantages, and future growth potential.

What is Gilead Sciences (GILD) and what does it do?

Gilead Sciences, Inc. is an American biopharmaceutical company founded in 1987. Headquartered in Foster City, Calif,Researching, developing, manufacturing, and marketing innovative treatments for serious diseases such as HIV/AIDS, hepatitis, and cancerexileThe following is a list of the most common problems with the "C" in the "C" column.

The company is particularly interested inWorld leader in the field of HIV drugsthrough its flagship products such as Biktarvy® and Genvoya®,Holds approximately 501 TP3T share of the HIV drug marketThe company is doing so. 

The company has also successfully developed several breakthrough drugs, including Harvoni® and Sovaldi® for hepatitis C and Lemdecivir® (Veklury®) for the treatment of novel coronaviruses.

Gilead Sciences' corporate information is as follows

• Company Name:Gilead Sciences, Inc.
• Year Established:1987
• Headquarters Location:Foster City, California, U.S.A.
• Representative:Daniel O'Day - Chairman and CEO
• Official site:https://www.gilead.com
• Business Development:More than 35 countries
• Main business areas:Development, manufacturing and marketing of drugs for HIV, viral hepatitis, COVID-19, cancer, inflammatory diseases, etc.

What is the corporate philosophy and vision of Gilead Sciences (GILD)?

Gilead Sciences has a corporate mission to "create a healthier world". The company's vision is to improve the lives of patients worldwide and address unmet needs in healthcare through innovative medicines.

The company's core values are as follows

• Integrity and EthicsWe will: operate our business in accordance with high ethical standards and fulfill our responsibilities to patients, healthcare professionals, and society as a whole.
• Inclusiveness and Diversity: Promote an inclusive work environment that respects diverse perspectives.
• Cooperation and CollaborationThe company creates innovative solutions through collaboration with internal and external partners.
• The Pursuit of Excellence: To provide the highest standard of pharmaceutical products through scientific rigor and commitment to quality.
• patient-centered way of thinkingThe patient's needs are paramount in all decisions.

Guilliard Sciences is committed to developing innovative treatments for serious diseases such as HIV/AIDS, hepatitis, and cancer based on these values. The company is also focused on improving access to healthcare, ensuring that patients around the world receive the treatment they need.

What are Gilead Sciences' (GILD) main services?

Gilead Sciences develops and delivers innovative medicines in the following key therapeutic areas

HIV/AIDS drugs

For more than 30 years, he has promoted research into the treatment, prevention, and cure of HIV infection.
Numerous innovations in HIV treatment, including the first single-agent regimen, the first oral drug to prevent HIV infection, and a long-acting HIV injection administered twice a year.
These efforts are helping to transform HIV into a treatable and preventable chronic disease.

drugs for the treatment of liver disease

Provides drugs for the treatment of hepatitis B and hepatitis C.Over the past decade, the development of hepatitis C (HCV) drugs has helped cure millions of patients.
It also offers treatment options for hepatitis B (HBV) and hepatitis D (HDV) and works to improve the quality of life of those suffering from these diseases.

COVID-19 Therapeutics

Developed therapeutic agents against novel coronavirus infection (COVID-19) to help overcome the pandemic. He has contributed to the recovery of COVID-19 patients and the reduction of the burden on the medical field.

oncology drug

The company has also entered the field of cancer treatment and is working to develop innovative therapies.
Particularly,Providing advanced therapies such as CAR T-cell therapyand expanding new treatment options for cancer patients. 

Inflammatory Disease Therapeutics

Developed therapeutic drugs for inflammatory diseases such as rheumatoid arthritis and ulcerative colitis to improve the quality of life of patients.
By providing new treatment options for these diseases, we are meeting an unmet medical need.

Through these product portfolios, Gilead Sciences continues to provide innovative treatment options for serious diseases. HIV drugs, in particular, provide a stable revenue stream for the company and play an important role in supporting the development and introduction of new products.

What is Gilead Sciences' (GILD) business model? How does it generate revenue?

Revenue model based on R&D and pharmaceutical sales

Gilead's largest source of revenue comes from the development and marketing of new drugs. Exclusive sales during the patent period will ensure a high profit margin.

• In-house new drug development
  
  • Research and development of innovative pharmaceutical products
  • Conduct clinical trials and obtain regulatory approvals (e.g., FDA)
  • Manufacture and sale of pharmaceutical products after obtaining approval
• Securing exclusive market share through patents
  
  • Maintain high profitability due to less competition during patent term
  • Typical product:
    • HIV drugsBiktarvy®, Genvoya®, Descovy®.
    • drugs for the treatment of liver diseaseHarvoni®, Sovaldi®.
    • oncology drugYescarta®, Trodelvy®.
    • COVID-19 TherapeuticsVeklury®.
• Global Expansion
  
  • Established worldwide sales network, with the majority of sales coming from markets outside the U.S.
  • Adjusting prices for emerging markets to increase revenues

Licensing revenue

Licensing of drugs developed by the company to other pharmaceutical companies,Royalty and milestone incomeThe mechanism to obtain the

• Types of Licensing
  
  • Granting of manufacturing and marketing rights: Outsource production and distribution of pharmaceuticals to other companies and earn royalties.
  • joint development agreementR&D in collaboration with other companies and share profits when successful.
• Examples of Typical Licensing Revenue
  
  • Providing generic versions of HIV and liver disease drugs for developing countries to increase scale
  • Joint projects for new drug development in partnership with biotechnology companies

Strategic Alliances and M&A

Gilead is actively pursuing alliances with biotech companies and mergers and acquisitions (M&A) to accelerate growth.

• Growth Strategy through M&A
  
  • Acquired a promising biotech company,Expand development pipeline (new drug candidates)
  • Acquired Kite Pharma, a CAR-T cell therapy company, to strengthen the oncology therapeutic area.
  • Acquired Immunomedics, developer of the breast cancer drug Trodelvy®.
• Technology platform acquisition
  
  • Entering new therapeutic areas such as gene therapy, cell therapy, and RNA technology
  • Promote AI-based drug discovery research

Profit Structure Characteristics

Gilead's revenue model has the following characteristics

• Stable revenue base for HIV drugs
  
  • Maintain dominant share of HIV market (approx. 501 TP3T) with annual sales of over $10 billion
• Ensure high profit margins during the exclusivity period of new drugs
  
  • Profit margin earned by mainstay products before patent expiration is more than 401 TP3T
• R&D expenses invested approx. 20% of sales
  
  • R&D investment in 2023 is about $5.7 billion
• Maximize revenue through global sales network
  
  • Ratio of sales in markets outside the U.S. increased

Gilead Sciences' business model is,R&D-oriented pharmaceutical companyThe company focuses on the development and sales of highly profitable new drugs, leveraging its strengths as a
In addition, the company maintains growth through licensing revenues and M&A strategies. In particular, HIV drugs have become a stable revenue base, and the company is working to achieve sustained growth through the introduction of new drugs.

What is the trading market?

Gilead Sciences, Inc. is listed on the NASDAQ stock exchange in the United States. Its ticker symbol is GILD.

What are the sectors, industries, and themes to which Gilead Sciences (GILD) belongs?

sector

Healthcare:. Gilead Sciences is a biopharmaceutical company dedicated to developing innovative medicines to prevent and treat life-threatening diseases. 

type of industry

Biotechnology:.The company is a biopharmaceutical company engaged in the research, development, and commercialization of therapeutics for diseases such as HIV, viral hepatitis, COVID-19, and cancer. 

Related Themes

Innovation in drug discovery through the use of AI technology:.Gilead Sciences is working to streamline the drug discovery process and accelerate new drug development through partnerships with companies that have AI technology-based drug discovery platforms.

Dividends?

Gilead Sciences has a dividend yield of approximately 2.941 TP3T.
For the past five yearsAverage annual dividend growth rateis about 4.10%

Who are Gilead Sciences' (GILD) competitors?

Gilead Sciences' (GILD) main competitors are.

• Merck (MRK):A leading U.S. pharmaceutical company that develops and markets HIV and cancer immunotherapy drugs, competing directly with Gilead. Particularly strong in innovative cancer drugs such as Keytruda.
• Bristol-Myers Squibb (BMY):A major U.S. pharmaceutical company. Competes with Gilead in the fields of immunotherapy and blood cancer drugs. Market leader in cancer immunotherapy drugs such as Opdivo and cell therapy.
• ABBV:A U.S. pharmaceutical company competing with Gilead in the areas of HIV and immunological disease drugs. Has established a particularly strong market position in immunological disease drugs such as Humira.
• Pfizer (PFE):Largest pharmaceutical company in the United States. Competes with Gilead in the fields of antiviral and oncology drugs; also known for the development and manufacture of COVID-19 vaccine.
• Novartis (NVS):Swiss pharmaceutical giant. Competes with Gilead in the field of cellular therapies and immune disease drugs, and leads the market with innovative therapies such as CAR-T cell therapy.

What is the size and growth potential of the industry to which Gilead Sciences (GILD) belongs?

Gilead Sciences, Inc. belongs toBiotechnology and pharmaceutical industryis experiencing sustained growth worldwide and is expected to continue to expand.

Global Market Size and Growth Projections

The overall market size of the biotechnology and pharmaceutical industries is projected to grow as follows

• Biotechnology Market
  
  • Market size in 2024: approx.US$761.5 billion
  • Projections for the year 2033:US$1,315.9 billion
  • Compound annual growth rate (CAGR): approx. 8-9%
  • Growth Factors:Development of genetic engineering, spread of personalized medicine, expansion of emerging markets
• Global Pharmaceutical Market
  
  • Market size in 2022: approx.1.48 trillion dollars
  • Projections for 2030:2.2 trillion dollars
  • Compound annual growth rate (CAGR): approx. 5-6%
  • Growth Factors:Aging population, increase in chronic diseases, innovation of new drugs

Key Factors Driving Growth

Demographic Changes

• Aging of the population: The global population over 65 years old is increasing, and the number of patients with chronic diseases such as cancer, cardiovascular disease, and dementia is rising.
• Growing demand for medical care in emerging countries: Demand for pharmaceuticals is increasing as medical infrastructures are being developed, especially in Asia and Africa.

technological innovation

• The Rise of Biopharmaceuticals: Biopharmaceuticals, such as antibody drugs, RNA vaccines, and gene therapy, have become mainstream.
• Gene and cell therapy: Advanced medical treatments such as CAR-T cell therapy are spreading, creating a new market.
• Use of AI and digital technology: Discovering new drug candidates through AI, streamlining clinical trials, and promoting personalized medicine.

Changes in the market environment

• Increase in medical expenditures: Governments are expanding their healthcare budgets and increasing investment in the pharmaceutical and biotechnology sectors.
• Streamlining the New Drug Approval ProcessExpansion of expedited approval systems by: FDA and EMA (European Medicines Agency).
• Strengthening pandemic preparedness: COVID-19 led to an increase in the importance of developing drugs and vaccines for infectious diseases, and countries focused on the biotech field.

High-profile growth areas

Oncology Drugs Market

• Market size in 2022: approx. 200 billion dollars
• 2030 forecast: over $350 billion
• Average annual growth rate: 7-8%
• growth factor:
  • Widespread use of immune checkpoint inhibitors and CAR-T cell therapy
  • Increase in the number of patients due to advances in early diagnosis techniques
  • Gilead's leading products such as Trodelvy®, Yescarta®, and Tecartus® drive this market

Rare Disease Drugs Market

• Continued market expansion and high profitability
• Promoting development through policy support:
  • Legislation to encourage the development of rare disease drugs in various countries (U.S.orphan drug designation systemetc.)
  • Areas where high drug pricing is possible and profit margins are high for pharmaceutical companies

Biosimilars Market

• Market expansion due to patent expiration
• Improved cost efficiency
• Increased demand in emerging countries
• Biosimilars (biosubsequent products) are becoming increasingly popular in order to reduce the high cost of biopharmaceuticals.
• Gilead is also looking to enter the biosimilars market in parallel with new drug development.

Gilead Sciences' Position and Future Prospects

Competition and positioning within the industry

• Leading companies in the HIV market: The Global HIV Therapeutics MarketApprox. 50% sharewith a
• Strengthening entry into the field of oncology treatment: Expanding its presence in the cancer treatment market with a focus on CAR-T cell therapy.
• Success of COVID-19 TherapeuticsWith: Lemdecivir (Veklury®), the company has established a strong position in the field of infectious disease drugs.

Strategies for Sustainable Growth

• Developing new markets: Expansion into the area of rare diseases and immunological diseases.
• Use of Strategic M&AAcquired a biotech company and gained a new technology platform.
• Introduction of digital technology: Improved efficiency of drug discovery through the use of AI and machine learning.

What are Gilead Sciences' (GILD) differentiators and advantages over the competition?

Gilead Sciences, Inc. differentiates itself from its competitors in the biotechnology industry by leveraging its unique strategies and strengths.

Extensive product portfolio and dominant market share

Gilead is,HIV drugs, hepatitis drugs, cancer drugs, new corona drugsThe company offers innovative drugs in several fields, including In particular, the company has established itself as a global leader in the HIV drug market and has developed several groundbreaking treatments.

• Market share of HIV drugs: Accounts for approx. 50% of the HIV drug market and forms a stable revenue base.

With a broad product portfolio and no dependence on specific disease areas, the company ensures business stability.

Market domination through blockbuster strategies

Gilead has developed a "blockbuster strategy" to introduce innovative drugs that significantly outperform existing treatments and gain an exclusive share of the market. The company maintains high profitability through exclusive sales during the patent term.

• Sovaldi®, a drug for hepatitis C, cost more than $10 billion in one yearsales, making it the fastest-selling blockbuster drug in history.
• Biktarvy®, an HIV drug, also established a competitive advantage with annual sales of more than $10 billion.

With this strategy, Gilead has overwhelming market dominance over its competitors.

Strong R&D and financial resources

Gilead invests heavily in the discovery and development of new drugs and accelerates the development of innovative therapies.

• Annual R&D expenditures (R&D investment)In 2023, it is expected to be about5.7 billion U.S. dollarsinjecting
• Extensive pipeline: Developing new drugs in diverse areas such as HIV, cancer, autoimmune diseases, infectious diseases, etc.
• Application of AI and biotechnology: Improving the efficiency of the drug discovery process and enhancing the development of next-generation therapies

Furthermore, backed by ample financial resources,Acquisition of venture firms and introduction of outside technologyto aggressively improve the speed of new drug development.

Strategic Partnerships and M&A

Gilead is actively pursuing alliances with other pharmaceutical and biotech companies,Facilitates sharing of skills and knowledgeThe company is doing so.

• Strengthening of Oncology: Leading company in CAR-T cell therapyAcquired Kite Pharma
• Expansion of Antibody Drugs: with the breast cancer drug Trodelvy®.Acquired Immunomedics
• Enhanced development of non-alcoholic steatohepatitis (NASH)License Agreement with Yuhan Yangheng Co.

Through these strategic alliances, the company is accelerating the development of new treatment methods and building a system that can respond quickly to market needs.

Global Market Expansion

Gilead is,Products in key markets around the worldand a global sales network.

• Approximately 50%+ of sales are generated from markets outside the U.S.
• Expansion into emerging marketsProviding HIV and Hepatitis C drugs for developing countries to improve access to healthcare
• Expand market share in the U.S., Europe and AsiaStrengthening cooperation with regulators with the aim of

This international market expansion has allowed for product proliferation and sales growth.

High profitability and financial strength

Gilead is,Efficient management, high profitability, and a stable financial baseThe following is a list of the most common problems with the "C" in the "C" column.

• Sales for the third quarter of 2023:7.1 billion U.S. dollars
• dividend yieldApprox.2.94%
• ROE (Return on Equity)Levels: Above industry average

In particular, sales of HIV drugs have been stable, supporting the company's overall financial base.

Guilliard Sciences (GILD) on its performance

The financial year of Gilead Sciences, Inc. ends on December 31 of each year.

The quarterly schedule of financial results announcements is as follows

• First Quarter ResultsLate April
• Second Quarter Financial ResultsEarly August
• Third Quarter ResultsEarly Nov.
• Fourth Quarter and Full Year ResultsEarly February of the following year

First, we will review the following four indicators to perform a minimum performance analysis of Gilead Sciences (GILD).

1. Sales:An indicator of a company's performance and growth.
2. Operating cash flow and operating cash flow margin:An indicator that looks at how much cash a company generates from its services. Margins are considered excellent when they are 15% of that ratio.
3. Operating Income:Profit earned by a company from its core business. An indicator to evaluate a company's performance.
4. Free Cash Flow:Free cash that a company keeps on hand. Indicates financial flexibility and business stability.
5. EPS:An indicator that looks at a company's earning power "profitability" and "growth potential" in terms of net income per share. The higher the number, the higher the profitability.

Each data is,Investing.com, ,TradingViewSee from

Gilead Sciences (GILD) Stock Price

View the current real-time stock price chart (TradingView) for Gilead Sciences (GILD).

The chart shows the Relative Strength Index (RSI). Reference as an indicator of market overheating.

*An overbought indicator when the RSI exceeds 70% to 80%, and conversely, an oversold indicator when the RSI falls below 20% to 30%.

Gilead Sciences (GILD) Quarterly: Sales Trends

Quarterly sales forecasts and actual sales and year-on-year changes.

Sales forecasts and actual results are shown in graphs.

Gilead Sciences (GILD) Quarterly: Operating Cash Flow and Free Cash Flow Trends

Quarterly operating cash flow, operating cash flow margin and free cash flow.

Each transition is shown in the graph below.

Gilead Sciences (GILD) Quarterly: Operating Income and Operating Margin Trends

Quarterly operating income and operating margin trends.

Each transition is shown in the graph below.

Gilead Sciences (GILD) Quarterly: EPS Trends

Quarterly EPS forecast and actual EPS.

Each transition is shown in the graph below.

Gilead Sciences (GILD) Full Year: Sales Trends

This is the sales forecast for the full year and actual sales and year-on-year changes.

Each transition is shown in the graph below.

Gilead Sciences (GILD) Full Year: Operating Cash Flow, Free Cash Flow Trends

Operating cash flow, operating cash flow margin and free cash flow for the full year.

Each transition is shown in the graph below.

Gilead Sciences (GILD) Full Year: Operating Income and Operating Margin Trends

The following is a trend of operating income and operating income margin for the full year.

Each transition is shown in the graph below.

Gilead Sciences (GILD) Full Year: EPS Trends

This is the EPS forecast and actual EPS for the full year.

Each transition is shown in the graph below.

What is the future life and outlook for Gilead Sciences (GILD)?

Gilead Sciences, Inc. is a biopharmaceutical company with a strong position in HIV and liver disease drugs.
In recent years, the company has strengthened its expansion into the oncology area (oncology) and aims to obtain 301 TP3T of its sales from the oncology area by the end of 2030. 

financials

In Q2 2024 results, sales and earnings per share exceeded market expectations, especially sales of the HIV drug Vicutarvi, which reached $3.8 billion, up 211 TP3T YoY. Sales of the oncology drug Trodervi were also strong and are expected to grow in the future.

Strategic Alliances and R&D

Through its alliance with Leo Pharma, Gilead is developing new therapies for inflammatory diseases. The company is also expanding its product portfolio and entering new therapeutic areas through aggressive investment in R&D and strategic M&A.

Future Outlook

Gilead is pursuing product development and market expansion in the oncology and inflammatory disease areas, while maintaining a stable revenue base from existing HIV and liver disease drugs. Through these strategic initiatives, Gilead expects to achieve sustained growth in the future.

What is Gilead Sciences' new drug pipeline?

Gilead Sciences is,Cancer immunotherapy, HIV treatment, and other innovative new drug developmentand providing new treatment options at the forefront of medicine. Currently, progress is expected to be made in the following areas, among others

Status of Cancer Immunotherapy Development

Gilead is accelerating its entry into the field of cancer treatment,Next Generation ImmunotherapyNoted as aAnti-TIGIT and anti-PD-1 antibodiesdevelopment is underway.

• Anti-TIGIT antibody
  
  • A new immune checkpoint inhibitor that is expected to be effective in releasing immune cell suppression and attacking cancer cells.
  • Present,Lung cancer, bladder cancer, breast cancerClinical trials are underway for the treatment of such diseases as
• Anti-PD-1 antibody
  
  • One of the immunotherapies already established in the market, GileadDevelopment of new PD-1 inhibitors with higher efficacyThe company is moving forward with
  • Combination therapy with anti-TIGIT antibodyThe strategy is to maximize the effectiveness of cancer immunotherapy by

Future Outlook

Gilead, by 2030.More than 20 new cancer drug indications approvedThe company is strengthening its presence in the oncology field with the goal of

The Future of Sunlenca, a Long-Acting HIV Drug

Gilead, which has a dominant market share in the field of HIV treatment, has developed a new treatment option, Sunlenca, a long-acting HIV drug.

• Sunlenca Features
  • Can be treated with one injection every six months.A long-acting HIV drug.
  • ConventionalSignificantly reduces the burden of daily HIV medicationsA revolutionary treatment method that
  • In 2022.US FDA and European EMA approvalsand is currently expanding its market.

Future Outlook

Gilead, starting with Sunlenca,Shifting HIV treatment from "daily medication" to "long-acting treatmentIn addition, the company has been promoting a strategy to make the company's employees In addition,Research Toward a Cure for HIVThe company also focuses on

Other Notable New Drugs

Gilead is not only for HIV and cancer,Inflammatory and autoimmune diseasesThe company is also developing new drugs in the field of

• Non-Alcoholic Steatohepatitis (NASH)
  
  • Currently developing innovative treatments for NASH for which no effective therapies exist.
  • Mechanisms that inhibit inflammation and fibrosisA new drug is currently in clinical trials to prevent the progression of liver disease by utilizing
• Ulcerative colitis and Crohn's disease treatment
  
  • Regulates the immune system and reduces inflammationOral JAK inhibitoris in clinical trials.
  • This makes it more effective than existing biologics inProviding treatment options that can be easily takenThe goal is to
• New coronavirus and RS virus (RSV) infection treatment
  
  • Veklury, a COVID-19 treatment, followed by new antiviral drugs for new coronas and RS virus infections.

Future Outlook

With these new drugs, Gilead is in addition to HIV and cancer,Aiming to expand the market in the areas of inflammatory and infectious diseasesEspecially in areas where treatment options are limited, such as NASH and ulcerative colitis.Practical Application of New Drugsis expected to be

Gilead Sciences (GILD) Full Year 2024 Financial Summary

Date of announcement: 25/02/12

Sales and Revenues

• Annual SalesUS$28.8 billion (+6% over the previous year)
• Sales of main products (excluding Veklury)26.8 billion U.S. dollars (+8% over previous year)
• HIV drug sales19.6 billion U.S. dollars (+8% over previous year)
  • Biktarvy.(HIV drugs): $13.4 billion (+13% YoY)
• Oncology SalesUS$3.2 billion (+12% over the previous year)
  • Trodelvy.(anticancer drugs): $1.3 billion (+24% YoY)
  • Yescarta & Tecartus(CAR-T therapy): $2.0 billion (+6% YoY)
• Sales of drugs for liver diseases3 billion U.S. dollars (+9% over the previous year)
• Veklury (COVID-19 treatment) SalesUS$1.8 billion (vs. -18% in the previous year)
• GAAP Net Income: $480 million (-91% over the previous year)
  • This is,4.7 billion in research and development costs related to the CymaBay acquisitionis affected by
• Non-GAAP Net Income: $5.795 billion (vs. -31% in the previous year)
• Earnings per share (EPS)
  • GAAP: $0.38 (YOY -92%)
  • Non-GAAP: $4.62 (YoY: -31%)

Increase in orders

• Biktarvy's growing share of the HIV marketSales growth due to
• Accelerating growth in the oncology field(Trodelvy, Yescarta expand market presence)
• Livdelzi in the liver disease area newly launched on the market
• HIV prophylaxis lenacapavir (one dose every six months) Preparations are underway for the summer 2025 launch of

Cash Flow

• Operating Cash FlowUS$10.8 billion (+35% over the previous year)
• free cash flowUS$10.3 billion
• Cash and marketable securitiesUS$9.9 billion (+18% over the previous year)
• dividend payment3 billion dollars
• stock buy-backUS$350 million

Performance by Region

• U.S. markets: accounts for about 711 TP3T of the total
• European Market: 161 TP3T overall (Biktarvy and Yescarta growth is significant)
• Asia and other regionsGrowing (especially demand for Yescarta is expanding)

Future Guidance (2025 Forecast)

• Annual Sales Forecast: $28.2 billion - $28.6 billion (vs. -2% in the previous year)
  • Decline in Veklury sales impacted (expected to shrink to $1.4 billion)
  • However, supplemented by growth in HIV and oncology
• Non-GAAP EPS: $7.70 - $8.10 (+67% vs. previous year)
• HIV area
  • Biktarvy continues to grow
  • **lenacapavir (half-dose HIV prophylaxis)** to be launched on the market in summer 2025
• Oncology
  • Expansion of Trodelvy's adaptation(expected FDA approval for the treatment of small cell lung cancer)
  • Yescarta and Tecartus Growth in CAR-T Therapy
• Dividend forecast for 2025$0.79/share (+3% y/y)

summary

• Maintain dominance in the HIV marketWhile,Shift oncology area to a growth pillarThe following is a list of the most common problems with the "C" in the "C" column.
• Reinforcement of R&D investment(HIV prophylaxis, liver disease drugs, cancer immunotherapy).
• Stable cash flowThe company will continue to aggressively pay dividends and buy back its own shares.
• Decline in Veklury sales will affect the company in the short term, but long-term growth prospects are solidThe following is a list of the most common problems with the "C" in the "C" column.

Gilead maintains growth in the HIV treatment market,Strategies aimed at accelerating growth in the oncology fieldThe introduction of the HIV prevention drug lenacapavir will be a major key to growth in 2025.Companies with stable cash flow and attractive for long-term investmentThe following is a list of the most common problems with the "C" in the "C" column.

Which brokerage firms can I buy shares of Gilead Sciences (GILD)?

The following is a list of major brokerages that offer shares of Gilead Sciences (GILD). At these brokerages, you can choose to invest as a CFD (Contract for Difference) as well as directly as a foreign stock.

I myself mainly use SBI Securities, but some stocks they handle may not be available for purchase. In such cases, I sometimes use CFDs at Saxo Bank Securities or IG Securities.

summary

We have taken a closer look at Gilead Sciences' (GILD) business, strengths, and competitive advantages.

The company is a biopharmaceutical company with a strong product portfolio centered on HIV drugs and high R&D capabilities. The company has established a stable revenue base and is proactive in returning profits to shareholders. Furthermore, the company is aggressively expanding into new areas such as oncology and inflammatory diseases, and its future growth strategy is attracting attention.

Combining a strong financial position, an innovative product portfolio, and an aggressive growth strategy, Gilead Sciences is one of the companies to watch closely in the future market trends.